Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story

FierceBiotechAs calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?

FierceBiotechOlympus pushes deeper into oncology with $270M BioProtect deal

Clinical OMICsHeart Attack Byproduct Linked to Brain Inflammation and Cognitive Decline

Endpoints NewsPost-Hoc Live: Jeremy Levin on biotech's existential moment

Endpoints NewsOutlook says FDA will sign off on its version of Avastin for wet AMD

BioWorldKennedy offers emergency immunity for use of MCM in hantavirus

BioWorldAhR you ready for this? A new (or not-so-new) approach in UC

BioWorldRegulatory actions for May 26, 2026

BioWorldFinancings for May 26, 2026

BioWorldIn the clinic for May 26, 2026

BioWorldOther news to note for May 26, 2026

BioPharma DiveEarly data for heart drug affirm Lilly’s billion-dollar bet on Verve